+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years - 55Years
All Genders
Healthy Volunteers
ID07883226

Phase 1 Study to Evaluate Safety, Tolerability, and Drug Interactions of TBD11 in Healthy Adults with Up to 84 Days of Daily Dosing

Led by Gates Medical Research Institute · Updated on 2026-10-22

66

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are conducting a Phase 1 clinical trial to evaluate the safety, tolerability, and pharmacokinetics of TBD11, a drug given in multiple doses to healthy adult volunteers aged 18 to 55. This trial also includes a study of drug-drug interactions where TBD11 is given with either a strong CYP3A inhibitor itraconazole or inducer rifampicin. The study has three cohorts Cohort 1 receives TBD11 or placebo daily for 14 days, Cohort 2 receives a single dose of TBD11 combined with itraconazole or rifampicin in two periods, and Cohort 3 receives TBD11 or placebo daily for up to 84 days.

CONDITIONS

Brief Title

A Phase 1 Multiple Dose Trial in Healthy Adult Participants to Evaluate the Safety, Tolerability, Drug-Drug Interactions, and Pharmacokinetics of TBD11

Research Team

G

Gates MRI

G

Gates MRI

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here